Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
Additional Resources Mercer: GLP-1 Considerations for 2026 Peterson-KFF: Employer Perspectives on GLP-1 Coverage Costs Blue Cross Blue Shield: How GLP-1s Could Increase Employer Premiums Morgan Lewis: GLP-1 Coverage, Obesity, and the ADA Related: ERISA Voluntary Benefits Compliance Checklist for Brokers (BenefitFlow) Sources for statistics cited in this article include SHRM, EBRI, HUB International, KFF, Mercer, Blue Cross Blue Shield Association, and the Business Group on Health
Utilizing singlenuclei RNA-sequencing, we identified the cellular phenotypes of AP/NTS GIPR- and GLP-1Rexpressing cells on distinct populations of inhibitory and excitatory neurons, with the greatest expression of GIPR in GABAergic neurons
Addressing the Shortage: Compounded Injectable Semaglutide and Tirzepatide at Restorative Compounding Pharmacy + Wellness In recent times, the demand for effective diabetes and weight loss treatments has significantly surged, leading to nationwide shortages of crucial medications like Ozempic, Wegovy, Mounjaro, and Zepbound
Presented for research literature review only Brady LJ et al